comparemela.com

Latest Breaking News On - Diamicron modified release controlled evaluation - Page 1 : comparemela.com

Effect of a multicomponent quality improvement strategy on sustained achievement of diabetes care goals and macrovascular and microvascular complications in South Asia at 6.5 years follow-up: Post hoc analyses of the CARRS randomized clinical trial

Nikhil Tandon and colleagues explore the impact of a quality improvement strategy for patients with type 2 diabetes 6.5 years after its implementation for the CARRS randomised trial.

India
United-kingdom
Denmark
Pakistan
Japan
Nimmi
Balochistan
United-states
Hyderabad
Andhra-pradesh
Mumbai
Maharashtra

Continuing ACE Inhibitors Despite Potassium Change Can Have Benefits

Investigators studied the effects of continuation vs discontinuation of ACE inhibitor therapy after hyperkalemia in type 2 diabetes

Australia
United-states
American
Toshiaki-ohkuma
University-of-new-south-wales
George-institute-for-global-health
Vascular-disease
Diamicron-modified-release-controlled-evaluation
George-institute
Global-health
New-south-wales
Clinical-journal

Continuing ACE Inhibitors Despite Potassium Change Can Have Benefits

Investigators studied the effects of continuation vs discontinuation of ACE inhibitor therapy after hyperkalemia in type 2 diabetes

Australia
United-states
American
Toshiaki-ohkuma
University-of-new-south-wales
George-institute-for-global-health
Vascular-disease
Diamicron-modified-release-controlled-evaluation
George-institute
Global-health
New-south-wales
Clinical-journal

Cumulative high BP is better for predicting cardiovascular and death risk in type 2 diabetes patients: JACC

Australia: Cumulative systolic blood pressure (SBP) may better predict major cardiovascular events in type 2 diabetes patients compared with traditional BP measures, a recent study in the Journal of.

Australia
Sydney
New-south-wales
Coll-cardiol
Nelson-wang
Royal-prince-alfred-hospital
Vascular-disease
Diamicron-modified-release-controlled-evaluation
Jacc
Cardiovascular-disease
Ype-2-disease

vimarsana © 2020. All Rights Reserved.